Last updated on April 17, 2014 at 7:54 EDT

Elsevier First to Publish NADAC Price Type from CMS

December 11, 2013

PHILADELPHIA, December 11, 2013 /PRNewswire/ –

Elsevier’s Gold Standard is the first drug database to include CMS’s
survey-based pricing, making it the most comprehensive source for drug price benchmarks

Elsevier [http://www.elsevier.com ], a world-leading provider of scientific, technical
and medical information products and services, announced today that, effective November
30, 2013, the Centers for Medicare & Medicaid Services’ (CMS) survey-based price type,
National Average Drug Acquisition Cost (NADAC)
[http://www.medicaid.gov/Medicaid-CHIP-Program-Information/By-Topics/Benefits/Prescription-Drugs/FUL-NADAC-Downloads/NADACMethodology.pdf ]
is included for all available drugs where
applicable in Elsevier’s Gold Standard Drug Database
[http://www.goldstandard.com/product/gold-standard-drug-database ] and web-based solutions,
[http://www.goldstandard.com/product/pricing-analyshttp:/www.goldstandard.com/product/pricing-analysis-cost-control/prospectorx/is-cost-control/prospectorx ]
and RxPrice Verify
[http://www.goldstandard.com/product/pricing-analysis-cost-control/rxprice-verify ].

CMS invested in NADAC, which is based on a monthly voluntary survey of randomly
selected pharmacies nationwide. NADAC was created in order to provide Medicaid agencies
with a better estimate of prices paid by pharmacies for drugs, which would be based upon
actual drug purchases. The NADAC file is updated on a weekly basis and each month a new
survey file is posted to reflect findings from the previous month’s survey results.
Elsevier publishes both the weekly price type file and monthly file.

“NADAC is another option for a new drug price benchmark that our customers, and the
industry as a whole, may decide to use,” said Kay Morgan, Vice President of Drug Products
and Industry Standards, Elsevier. “We at Elsevier strive to provide the most accurate and
continuously updated data for our users.”

Elsevier’s Gold Standard Drug Database pricing file is the only compendia that
continues to publish Average Wholesale Price (AWP), along with several other price types:
Wholesale Acquisition Cost (WAC), Direct Price (DP), Federal Supply Schedule (FSS), CMS
Federal Upper Limit (CMS-FUL), Maximum Allowable Cost (MAC), and Predictive Acquisition
Cost (PAC). Elsevier’s drug pricing database delivers the most up-to-the-minute data
available via web-based solutions, ProspectoRx and RxPrice Verify.

For more information about Elsevier’s Gold Standard, visit


About Elsevier

Elsevier is a world-leading provider of scientific, technical and medical information
products and services. The company works in partnership with the global science and health
communities to publish more than 2,000 journals, including The Lancet
[http://www.thelancet.com ] and Cell [http://www.cell.com ], and close to 20,000 book
titles, including major reference works from Mosby and Saunders. Elsevier’s online
solutions include ScienceDirect [http://www.sciencedirect.com ], Scopus
[http://www.scopus.com ], SciVal [http://info.scival.com ], Reaxys
[http://www.elsevier.com/reaxys ], ClinicalKey [https://www.clinicalkey.com ] and Mosby’s
Suite [http://www.confidenceconnected.com ], which enhance the productivity of science and
health professionals, helping research and health care institutions deliver better
outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier [http://www.elsevier.com ]
employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC
[http://www.reedelsevier.com ], a world-leading provider of professional information
solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly
owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext
Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

        Media contact
        Christopher Capot
        Director, Corporate Relations, Elsevier

SOURCE Elsevier

Source: PR Newswire